B
Bionetix Therapeutics
A developer of anticancer drugs designed for cancer treatment
About Bionetix Therapeutics
Bionetix Therapeutics, an entity based in Suwon, South Korea, operates within the biotechnology sector, focusing on the development of novel small molecule drugs. Founded in February 2017, the company directs its research and development efforts toward oncology and ophthalmology. The Chief Executive Officer is Doo-young Jung.
The company's business model centers on advancing its pipeline of drug candidates through clinical trials to address unmet medical needs. Bionetix in-licenses promising compounds from research institutions and progresses them through the development stages. A key collaboration was established in 2017 with Southern Research, a U.S.-based nonprofit research organization, to co-develop a new anti-cancer drug. This agreement provides Bionetix with the option to acquire exclusive global commercialization rights for the resulting inhibitors.
The therapeutic pipeline includes two primary candidates. The first, NTX-301, is a DNA methyltransferase (DNMT) inhibitor intended for the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). This epigenetic approach works by restoring the expression of specific genes to induce the differentiation of cancer cells. Bionetix in-licensed NTX-301 from Southern Research in 2017. The second lead candidate, NTX-101, is being developed for glaucoma. It functions by inhibiting an enzyme to normalize steroid metabolism in ocular tissues, aiming to control intraocular pressure and protect ocular tissue. The company is also developing other therapeutic candidates for oncology.
To finance its operations, Bionetix has successfully raised capital from institutional investors. A notable Series B funding round in January 2020 secured ₩10.8 billion (US$9.33 million), bringing its total funding at the time to ₩14.7 billion. The funds were allocated to advance NTX-301 into a Phase I clinical trial in the U.S. and to further the research and development of NTX-101. Investors in this round included Partners Investment, Stic Ventures, and KB Investment, among others.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2025 | $58M | $232M | Undisclosed | ↗ |
| SERIES BOther financing | Jan 2020 | $9.3M | $37M | Undisclosed | — |
Growth signals
Latest recorded traffic for Bionetix Therapeutics is 0 monthly website visits, down 100% over the last three months. Bionetix Therapeutics's team declined 28.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bionetix Therapeutics in the Suwon ecosystem
The Bionetix Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Mirae Asset Venture Investment
K Partners
Series A1 investor entered at this stage
Partners Investment
Other known investors1 additional known investor
Korea Research Institute Of Chemical Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bionetix Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bionetix Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










